PBS Biotech Receives Prestigious Award for Cell Products Development in 2026
On July 21, 2026, PBS Biotech, renowned for its cutting-edge single-use bioreactor technologies, proudly announced its recognition as the Cell Therapy Products Development of the Year 2026 by Life Sciences Review. This prestigious accolade positions the company among the leaders in the cell and gene therapy sector, spotlighting its pivotal role in enhancing the manufacturing processes of advanced therapies.
At the heart of PBS Biotech’s achievement is its unwavering commitment to overcoming the complexities that manufacturers face in scaling cell therapy production while ensuring the utmost quality of the cells involved. Central to this innovation is the patented Vertical-Wheel® bioreactor technology. This unique design facilitates delicate, low-shear cell culture environments, fostering the growth and differentiation of various sensitive cell types, from the initial stages of process development to large-scale commercial production.
Martin Simonetti, the CEO of PBS Biotech, shared insights on the transformative impact of cell therapies on modern medicine, emphasizing the urgent need for advanced manufacturing technologies that can harmonize scalability with cell quality. "As cell therapies continue to revolutionize healthcare, it is crucial for manufacturers to adopt solutions that do not compromise the integrity of the cells," Simonetti remarked. The acknowledgment from Life Sciences Review reaffirms PBS Biotech’s mission to provide manufacturing solutions that enhance the accessibility of these life-altering therapies for patients in need.
The Vertical-Wheel platform stands out in contrast to traditional stirred-tank bioreactors, as it was meticulously engineered to create consistent mixing conditions while maintaining low shear forces. This capability makes it especially suited for handling sensitive cell types, including induced pluripotent stem cells (iPSCs), mesenchymal stem cells (MSCs), T cells, NK cells, CAR-T, CAR-NK, and pancreatic islet cells. The platform offers linear scalability, which simplifies the transition from research phases to commercial manufacturing and drives swift technology implementation.
Life Sciences Review's feature on PBS Biotech praised the company’s customer-centric development approach, its dedication to continuous innovation, and its growing collaboration footprint within the cell and gene therapy landscape. The publication lauded PBS Biotech's efforts to address significant manufacturing hurdles, as a growing number of cell therapies are poised for commercial application.
“This award is a collective achievement for our employees, customers, and partners who are tirelessly pushing the boundaries of regenerative medicine," Simonetti stated. He highlighted the collaboration among various stakeholders as pivotal in laying the groundwork for the future of cell therapy manufacturing.
With an increasing demand for robust and scalable manufacturing solutions, PBS Biotech remains at the forefront of innovation, constantly expanding its technology offerings to support its clients. The company is dedicated to enhancing the success of its partners and streamlining the commercialization processes for cutting-edge therapies that hold the potential to transform lives.
PBS Biotech is not only focused on its immediate successes but also on the broader vision of shaping the future of biotechnological advancements. By fostering partnerships with leading biotech enterprises, Contract Development and Manufacturing Organizations (CDMOs), and academic institutions globally, PBS Biotech is committed to expediting the development and launch of promising cell therapies that can benefit patients worldwide. Whether they are treating degenerative diseases or providing new hope for regenerative medicine, the work being done at PBS Biotech exemplifies the evolving landscape of healthcare and the future direction of biomanufacturing industries.
At the heart of PBS Biotech’s achievement is its unwavering commitment to overcoming the complexities that manufacturers face in scaling cell therapy production while ensuring the utmost quality of the cells involved. Central to this innovation is the patented Vertical-Wheel® bioreactor technology. This unique design facilitates delicate, low-shear cell culture environments, fostering the growth and differentiation of various sensitive cell types, from the initial stages of process development to large-scale commercial production.
Martin Simonetti, the CEO of PBS Biotech, shared insights on the transformative impact of cell therapies on modern medicine, emphasizing the urgent need for advanced manufacturing technologies that can harmonize scalability with cell quality. "As cell therapies continue to revolutionize healthcare, it is crucial for manufacturers to adopt solutions that do not compromise the integrity of the cells," Simonetti remarked. The acknowledgment from Life Sciences Review reaffirms PBS Biotech’s mission to provide manufacturing solutions that enhance the accessibility of these life-altering therapies for patients in need.
The Vertical-Wheel platform stands out in contrast to traditional stirred-tank bioreactors, as it was meticulously engineered to create consistent mixing conditions while maintaining low shear forces. This capability makes it especially suited for handling sensitive cell types, including induced pluripotent stem cells (iPSCs), mesenchymal stem cells (MSCs), T cells, NK cells, CAR-T, CAR-NK, and pancreatic islet cells. The platform offers linear scalability, which simplifies the transition from research phases to commercial manufacturing and drives swift technology implementation.
Life Sciences Review's feature on PBS Biotech praised the company’s customer-centric development approach, its dedication to continuous innovation, and its growing collaboration footprint within the cell and gene therapy landscape. The publication lauded PBS Biotech's efforts to address significant manufacturing hurdles, as a growing number of cell therapies are poised for commercial application.
“This award is a collective achievement for our employees, customers, and partners who are tirelessly pushing the boundaries of regenerative medicine," Simonetti stated. He highlighted the collaboration among various stakeholders as pivotal in laying the groundwork for the future of cell therapy manufacturing.
With an increasing demand for robust and scalable manufacturing solutions, PBS Biotech remains at the forefront of innovation, constantly expanding its technology offerings to support its clients. The company is dedicated to enhancing the success of its partners and streamlining the commercialization processes for cutting-edge therapies that hold the potential to transform lives.
PBS Biotech is not only focused on its immediate successes but also on the broader vision of shaping the future of biotechnological advancements. By fostering partnerships with leading biotech enterprises, Contract Development and Manufacturing Organizations (CDMOs), and academic institutions globally, PBS Biotech is committed to expediting the development and launch of promising cell therapies that can benefit patients worldwide. Whether they are treating degenerative diseases or providing new hope for regenerative medicine, the work being done at PBS Biotech exemplifies the evolving landscape of healthcare and the future direction of biomanufacturing industries.
Topics Other）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.